DMK Pharmaceuticals Corporation
DMKPQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $2 |
| % Growth | 30.5% | -99.5% | -32.4% | – |
| Cost of Goods Sold | $0 | $0 | $2 | $3 |
| Gross Profit | -$0 | -$0 | -$0 | -$1 |
| % Margin | -3,658.8% | -6,263.4% | -30.1% | -32.5% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $0 | $4 | $0 | $0 |
| SG&A Expenses | $3 | $4 | $5 | $3 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $4 | $6 | $4 |
| Operating Income | -$3 | -$5 | -$6 | -$4 |
| % Margin | -36,030.7% | -68,603.2% | -442.4% | -201.9% |
| Other Income/Exp. Net | $2 | -$2 | -$3 | $1 |
| Pre-Tax Income | -$2 | -$7 | -$9 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$9 | -$9 | -$3 |
| % Margin | -15,317.2% | -123,457.5% | -615.5% | -154.7% |
| EPS | -0.2 | -3.34 | -4.09 | -1.55 |
| % Growth | 94% | 18.3% | -163.9% | – |
| EPS Diluted | -0.2 | -3.34 | -4.09 | -1.55 |
| Weighted Avg Shares Out | 7 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 7 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$7 | -$6 | -$3 |
| % Margin | -18,811% | -99,014.1% | -434.8% | -141.1% |